183 related articles for article (PubMed ID: 32958005)
21. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
Li H; Zeng J; Shen K
Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
[TBL] [Abstract][Full Text] [Related]
22. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells.
Kumar S; Bryant CS; Chamala S; Qazi A; Seward S; Pal J; Steffes CP; Weaver DW; Morris R; Malone JM; Shammas MA; Prasad M; Batchu RB
Mol Cancer; 2009 Apr; 8():26. PubMed ID: 19386116
[TBL] [Abstract][Full Text] [Related]
23. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
25. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.
Zhou J; Jiang YY; Chen H; Wu YC; Zhang L
Cell Prolif; 2020 Feb; 53(2):e12739. PubMed ID: 31820522
[TBL] [Abstract][Full Text] [Related]
26. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
27. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
[TBL] [Abstract][Full Text] [Related]
28. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
29. Amelioration of human peritoneal mesothelial cell co-culture-evoked malignant potential of ovarian cancer cells by acacetin involves LPA release-activated RAGE-PI3K/AKT signaling.
Tian M; Tang Y; Huang T; Liu Y; Pan Y
Cell Mol Biol Lett; 2021 Dec; 26(1):51. PubMed ID: 34886812
[TBL] [Abstract][Full Text] [Related]
30. Chrysin attenuates progression of ovarian cancer cells by regulating signaling cascades and mitochondrial dysfunction.
Lim W; Ryu S; Bazer FW; Kim SM; Song G
J Cell Physiol; 2018 Apr; 233(4):3129-3140. PubMed ID: 28816359
[TBL] [Abstract][Full Text] [Related]
31. A systems biology case study of ovarian cancer drug resistance.
Chen JY; Shen C; Yan Z; Brown DP; Wang M
Comput Syst Bioinformatics Conf; 2006; ():389-98. PubMed ID: 17369659
[TBL] [Abstract][Full Text] [Related]
32. A network pharmacology approach and experimental validation to investigate the anticancer mechanism and potential active targets of ethanol extract of Wei-Tong-Xin against colorectal cancer through induction of apoptosis via PI3K/AKT signaling pathway.
Lin F; Zhang G; Yang X; Wang M; Wang R; Wan M; Wang J; Wu B; Yan T; Jia Y
J Ethnopharmacol; 2023 Mar; 303():115933. PubMed ID: 36403742
[TBL] [Abstract][Full Text] [Related]
33. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway.
Zhang S; Leng T; Zhang Q; Zhao Q; Nie X; Yang L
Biomed Pharmacother; 2018 Jun; 102():302-308. PubMed ID: 29571014
[TBL] [Abstract][Full Text] [Related]
34. The Mechanism of Xiaoyao San in the Treatment of Ovarian Cancer by Network Pharmacology and the Effect of Stigmasterol on the PI3K/Akt Pathway.
Li M; Zhang W; Yang L; Wang H; Wang Y; Huang K; Zhang W
Dis Markers; 2021; 2021():4304507. PubMed ID: 34306252
[TBL] [Abstract][Full Text] [Related]
35. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
36. Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.
Nagaraj AB; Wang QQ; Joseph P; Zheng C; Chen Y; Kovalenko O; Singh S; Armstrong A; Resnick K; Zanotti K; Waggoner S; Xu R; DiFeo A
Oncogene; 2018 Jan; 37(3):403-414. PubMed ID: 28967908
[TBL] [Abstract][Full Text] [Related]
37. FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5.
Huang Y; Jin H; Liu Y; Zhou J; Ding J; Cheng KW; Yu Y; Feng Y
Endocr Relat Cancer; 2011 Feb; 18(1):13-26. PubMed ID: 20943720
[TBL] [Abstract][Full Text] [Related]
38. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
[TBL] [Abstract][Full Text] [Related]
39. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
40. Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway.
Cui Y; Zhou J; Rong F
Biochem Biophys Res Commun; 2020 Dec; 533(4):665-671. PubMed ID: 33051060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
